HeartSciences Inc. (HSCSW) Stock Analysis

Company Overview

HeartSciences Inc. operates as a medical technology company dedicated to advancing clinical diagnostics through the application of artificial intelligence-based technology to electrocardiography (ECG) data. The company develops AI-enhanced electrocardiography solutions and proprietary algorithms designed specifically to detect impaired cardiac relaxation or cardiac dysfunction, thereby expanding the clinical usefulness of standard ECG readings. Although the company operates within the medical technology sector, specific industry classifications and broader sector definitions are not publicly disclosed in the available data. The organization maintains a lean operational structure with a workforce of 15 employees, generating trailing twelve-month revenue of $8,669. These financial figures, combined with the absence of disclosed market capitalization data, indicate that HeartSciences Inc. functions as a micro-cap entity with a very limited revenue base relative to established large-cap competitors in the healthcare technology space.

Financial Health

The company reported trailing twelve-month revenue of $8,669 alongside a net income of $-8,485,301 and an EBITDA of $-7,768,315, revealing a significant negative gap between revenue and net income that suggests substantial operational costs or one-time expenses are being deducted from the bottom line. Free cash flow stands at $-4,213,324, which indicates that the company is currently consuming cash rather than generating it, thereby limiting its immediate financial flexibility for organic expansion without external financing. The gross margin is reported at 57.9%, while the operating margin is listed as -89939.6% and the profit margin at 0.0%; the negative operating margin reflects that operating expenses far exceed gross profit, a common characteristic in early-stage biotech or medical device firms with high R&D or development overhead. In terms of liquidity and leverage, the company holds $3.40M in cash against $3.87M in debt, resulting in a debt-to-equity ratio of 145.81% that characterizes a highly leveraged balance sheet where liabilities significantly outweigh equity. The current ratio of 1.19 suggests that the company possesses just enough current assets to cover its current liabilities, indicating a tight but technically solvency-positive short-term liquidity position. Return on Equity is -382.3% and Return on Assets is -73.5%, metrics that reveal management has yet to generate positive returns on the capital invested in the business, a typical challenge for companies still in the development phase of their core AI-ECG technology.

Valuation Assessment

Trailing P/E and forward P/E ratios are not available for HeartSciences Inc. due to the company's negative earnings, a situation common among firms that have not yet achieved profitability. The price-to-book ratio is 0.14, which indicates that the market values the company at a fraction of its book value, suggesting a deep discount or a valuation based on speculative future potential rather than current asset backing. Since price-to-sales and EV/EBITDA metrics are not disclosed, alternative valuation comparisons to larger peers are not possible within the provided data constraints. The 52-week high and 52-week low are both listed at $0.12, meaning the stock is currently trading at the exact level of its annual range with no intrayear volatility recorded in the provided metrics. The beta value of 2.54 implies that the stock price is expected to be approximately 2.54 times as volatile as the broader market, exposing investors to significant price swings during periods of market turbulence.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are not available in the current dataset, preventing a direct comparison of the pace at which earnings are growing relative to revenue. The company does not pay a dividend, as indicated by the absence of a dividend yield and payout ratio, meaning it reinvests all available resources or relies on external capital to fund operations and development. Consequently, the company's growth profile is entirely dependent on its ability to transition from cash consumption to cash generation rather than providing income through shareholder distributions. The overall financial picture presents a high-risk, high-volatility profile with no current income yield and limited historical growth data to assess future trajectory.